FR16C0028I1 - Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques - Google Patents
Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiquesInfo
- Publication number
- FR16C0028I1 FR16C0028I1 FR16C0028C FR16C0028I1 FR 16C0028 I1 FR16C0028 I1 FR 16C0028I1 FR 16C0028 C FR16C0028 C FR 16C0028C FR 16C0028 I1 FR16C0028 I1 FR 16C0028I1
- Authority
- FR
- France
- Prior art keywords
- viral vectors
- therapeutic methods
- vectors
- methods
- treat disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16661—Methods of inactivation or attenuation
- C12N2710/16662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16671—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27906901P | 2001-03-27 | 2001-03-27 | |
PCT/US2002/009512 WO2002076216A1 (fr) | 2001-03-27 | 2002-03-27 | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques |
Publications (2)
Publication Number | Publication Date |
---|---|
FR16C0028I1 true FR16C0028I1 (fr) | 2016-07-22 |
FR16C0028I2 FR16C0028I2 (fr) | 2018-05-11 |
Family
ID=23067509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR16C0028C Active FR16C0028I2 (fr) | 2001-03-27 | 2016-06-15 | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques |
Country Status (9)
Country | Link |
---|---|
US (6) | US7749745B2 (fr) |
EP (1) | EP1381280B1 (fr) |
JP (2) | JP4212897B2 (fr) |
AT (1) | ATE508635T1 (fr) |
AU (1) | AU2002306919B2 (fr) |
CA (1) | CA2441663C (fr) |
ES (1) | ES2366608T3 (fr) |
FR (1) | FR16C0028I2 (fr) |
WO (1) | WO2002076216A1 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6379674B1 (en) * | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
EP1381280B1 (fr) | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques |
AU2003216502B2 (en) * | 2002-03-01 | 2008-04-10 | Sloan-Kettering Institute For Cancer Research | Prevention of recurrence and metastasis of cancer |
US7655459B2 (en) * | 2004-03-31 | 2010-02-02 | Tomoki Todo | Enhancer of anticancer activity in viral therapy and method of preventing or treating cancer |
WO2005103237A1 (fr) * | 2004-03-31 | 2005-11-03 | Tomoki Todo | Procede de construction d'un virus de l'herpes simplex recombinant |
WO2006002394A2 (fr) | 2004-06-24 | 2006-01-05 | New York University | Souches de virus d'herpes simplex oncolytique non virulent modifiees pour bloquer la reponse hote innee |
EP2307033A4 (fr) * | 2008-05-29 | 2012-06-13 | Gen Hospital Corp | Utilisation de virus herpes oncolytiques pour tuer des cellules souches cancéreuses |
US9267151B2 (en) * | 2008-08-20 | 2016-02-23 | Brainco Biopharma, S.L. | STXBP1 overexpressing mouse and its uses in screening of treatments for neuropsychiatric illness |
WO2011101912A1 (fr) | 2010-02-19 | 2011-08-25 | 国立大学法人東京大学 | Virus de l'herpès recombinant et composition pharmaceutique contenant le virus de l'herpès recombinant |
EP2550362B1 (fr) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Glycoprotéines du cmv et vecteurs recombinés |
EP2753355B1 (fr) | 2011-09-08 | 2018-10-24 | New York University | Virus herpès simplex oncolytique et ses utilisations thérapeutiques |
DK3184641T3 (da) | 2013-10-28 | 2020-08-03 | Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education | Onkolytisk hsv-vektor |
MA39818A (fr) | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
CN107580626A (zh) | 2014-12-18 | 2018-01-12 | 美国安进公司 | 稳定冷冻病毒制剂 |
EP3307330B1 (fr) | 2015-06-15 | 2021-03-10 | New York University | Méthode de traitement utilisant des virus oncolytiques |
CA3010987A1 (fr) | 2016-01-08 | 2017-07-13 | Replimune Limited | Lignee de virus de l'herpes simplex oncolytique de type i |
RU2749050C2 (ru) | 2016-01-27 | 2021-06-03 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
EP3474889A4 (fr) | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | Vecteurs de cytomégalovirus de recombinaison utilisés comme vaccins contre la tuberculose |
AU2017290828A1 (en) | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
US20200009204A1 (en) | 2017-03-15 | 2020-01-09 | Amgen Inc. | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
CN106974942A (zh) * | 2017-05-03 | 2017-07-25 | 武汉滨会生物科技股份有限公司 | 重组溶瘤ii型单纯疱疹病毒在制备抗淋巴瘤、食道癌、乳腺癌、胰腺癌药物中的应用 |
EP3658165A4 (fr) | 2017-07-26 | 2021-09-01 | Oncorus, Inc. | Vecteurs viraux oncolytiques et leurs utilisations |
CN111164100B (zh) | 2017-08-03 | 2024-03-12 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
CN111246883A (zh) | 2017-08-07 | 2020-06-05 | 美国安进公司 | 用抗pd-l1抗体和溶瘤病毒治疗三阴性乳癌或结肠直肠癌伴随肝转移 |
JP7150823B2 (ja) | 2017-09-08 | 2022-10-11 | アムジエン・インコーポレーテツド | KRas G12Cの阻害剤及びそれを使用する方法 |
EP3697806A4 (fr) | 2017-10-17 | 2021-10-27 | International AIDS Vaccine Initiative, Inc. | Cassettes d'antigènes de la tuberculose |
EP3731850A4 (fr) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | Administration par un virus oncolytique de polypeptides thérapeutiques |
CR20210319A (es) | 2018-01-12 | 2021-07-27 | Amgen Inc | ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330) |
JP7429046B2 (ja) | 2018-03-30 | 2024-02-07 | 具紀 藤堂 | 腫脹発生抑制型腫瘍溶解性ウイルス |
EP3653716A1 (fr) * | 2018-11-19 | 2020-05-20 | HSF Pharmaceuticals | Vecteurs de virus alpha-herpès contrôlés de réplication et leurs utilisations |
MX2021007639A (es) | 2018-12-27 | 2021-08-11 | Amgen Inc | Formulaciones de virus liofilizadas. |
CN113439123A (zh) | 2019-03-05 | 2021-09-24 | 安进公司 | 溶瘤病毒用于治疗癌症的用途 |
TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
US20230147832A1 (en) * | 2020-01-22 | 2023-05-11 | City Of Hope | Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer |
WO2024038857A1 (fr) * | 2022-08-16 | 2024-02-22 | 具紀 藤堂 | Composition pharmaceutique contenant un vecteur viral d'herpès simplex |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2659628B1 (fr) * | 1990-03-16 | 1992-09-18 | Marin S Communication | Dispositif de boite ou d'etui a couvercle mobile. |
CA2039921A1 (fr) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfert et expression de la sequence d'adn dans les cellules du systeme nerveux central a l'aide de mutants du virus de l'herpes, avec deletions chez les genes en vue de repliquer le virus |
GB9102126D0 (en) | 1991-01-31 | 1991-03-13 | Smithkline Beecham Biolog | Novel vaccine |
US5750398A (en) | 1993-11-30 | 1998-05-12 | David C. Johnson | Vector, element and method for inhibiting immune recognition |
US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
US6261552B1 (en) * | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
GB9615794D0 (en) * | 1996-07-26 | 1996-09-04 | Medical Res Council | Mutant herpes simplex virus strains and uses thereof |
US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
DE60107203T3 (de) * | 2000-01-21 | 2009-07-23 | Biovex Ltd. | Herpes-virusstämme für die gentherapie |
AU6814601A (en) * | 2000-06-01 | 2001-12-11 | Sloan Kettering Inst Cancer | Use of mutant herpes viruses and anticancer agents in the treatment of cancer |
EP1381280B1 (fr) * | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques |
-
2002
- 2002-03-27 EP EP02753865A patent/EP1381280B1/fr not_active Expired - Lifetime
- 2002-03-27 ES ES02753865T patent/ES2366608T3/es not_active Expired - Lifetime
- 2002-03-27 CA CA2441663A patent/CA2441663C/fr not_active Expired - Lifetime
- 2002-03-27 WO PCT/US2002/009512 patent/WO2002076216A1/fr active Application Filing
- 2002-03-27 JP JP2002574742A patent/JP4212897B2/ja not_active Expired - Lifetime
- 2002-03-27 US US10/107,036 patent/US7749745B2/en active Active
- 2002-03-27 AT AT02753865T patent/ATE508635T1/de not_active IP Right Cessation
- 2002-03-27 AU AU2002306919A patent/AU2002306919B2/en not_active Expired
-
2008
- 2008-09-22 JP JP2008242828A patent/JP2009060907A/ja active Pending
-
2010
- 2010-03-11 US US12/721,599 patent/US8470577B2/en not_active Expired - Lifetime
-
2013
- 2013-06-24 US US13/924,936 patent/US8871193B2/en not_active Expired - Lifetime
-
2014
- 2014-10-27 US US14/524,163 patent/US9555072B2/en not_active Expired - Lifetime
-
2016
- 2016-06-15 FR FR16C0028C patent/FR16C0028I2/fr active Active
- 2016-12-19 US US15/383,578 patent/US10532095B2/en not_active Expired - Fee Related
-
2020
- 2020-01-10 US US16/739,890 patent/US20200345835A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9555072B2 (en) | 2017-01-31 |
JP2009060907A (ja) | 2009-03-26 |
JP2004528836A (ja) | 2004-09-24 |
US20200345835A1 (en) | 2020-11-05 |
US8871193B2 (en) | 2014-10-28 |
JP4212897B2 (ja) | 2009-01-21 |
WO2002076216A1 (fr) | 2002-10-03 |
US10532095B2 (en) | 2020-01-14 |
EP1381280A1 (fr) | 2004-01-21 |
FR16C0028I2 (fr) | 2018-05-11 |
US20020187163A1 (en) | 2002-12-12 |
ES2366608T3 (es) | 2011-10-21 |
US20150071965A1 (en) | 2015-03-12 |
US20130280299A1 (en) | 2013-10-24 |
EP1381280A4 (fr) | 2006-06-14 |
CA2441663C (fr) | 2013-01-22 |
ATE508635T1 (de) | 2011-05-15 |
US20170290908A1 (en) | 2017-10-12 |
AU2002306919B2 (en) | 2007-11-22 |
CA2441663A1 (fr) | 2002-10-03 |
US7749745B2 (en) | 2010-07-06 |
US20110070262A1 (en) | 2011-03-24 |
US8470577B2 (en) | 2013-06-25 |
EP1381280B1 (fr) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR16C0028I2 (fr) | Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques | |
DK1556021T3 (da) | Farmaceutiske sammensætninger omfattende flavonoider og menthol samt fremgangsmåder til behandling med brug af nævnte sammensætninger | |
NO20053817D0 (no) | Preparater og fremgangsmater for antiviral kombinasjonsterapi. | |
DK1368060T3 (da) | HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme | |
NO20041917L (no) | Spesifikke midler som binder humant angiopoietin-2 | |
BR0309665A (pt) | Tratamento de deficiência de alfa-galactosidase a | |
BRPI0411900A (pt) | compostos antivirais e métodos | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
ATE376832T1 (de) | Verzögert freisetzende formulierungen von oxymorphon | |
BRPI0412845A (pt) | herpes-vìrus, uso de um vìrus, composição farmacêutica, e, método de tratamento de um tumor em um indivìduo em necessidade do mesmo | |
DE60137337D1 (de) | Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene | |
WO2003032916A3 (fr) | Organosulfures inhibiteurs de tyrosine phosphatases | |
HUP0303917A2 (hu) | Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére | |
CY1107531T1 (el) | Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου | |
DK1097173T3 (da) | Anvendelse af peptider af IL-2 og derivater deraf som terapeutiske midler | |
MXPA04006572A (es) | Terapia de combinacion antivirica. | |
CL2004000261A1 (es) | Procedimiento para la eliminacion de virus en soluciones de fibrinogeno de aplicacion terapeutica. | |
DK1381382T3 (da) | Fremgangsmåder og præparater til behandling af öjensygdomme | |
EA200400399A1 (ru) | Способы лечения легочных заболеваний | |
DE602005016552D1 (de) | Parapocken-viren in kombination mit anderen antiviralen mitteln zur behandlung von hiv/aids | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
EA200000909A1 (ru) | ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА | |
DK1461042T3 (da) | Anvendelse af desoxypeganin til behandling af klinisk depression | |
NO20005548L (no) | Mykobakterieinhibitorer |